Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14 CHANGES TO VERSION 13

PUBLISHED APRIL 2019

Changes to v13

Lines removed

SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER ADULT TA'S (TA195, TA373, ABATACEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE √ MEDICINES FOR CHILDREN TA375) POLICY) Now covered by comment 8

PAEDIATRIC INDICATIONS (IN AS PER TA455 OR ADULT TA'S (TA130 LINE WITH NHS ENGLAND (replaced by TA375), TA143 (repalced by ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ MEDICINES FOR CHILDREN TA383), TA146, TA187, TA199, TA329, POLICY) TA392, TA460) Now covered by comment 8 ALBUTREPENONACOG ALFA HAEMOPHILIA B PRODUCTS ON CMU Blood factor products simplified NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 √ FRAMEWORK to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 AS PER BCSH GUIDELINES ANTIHAEMOPHILIC FACTOR/VON BCSH PRODUCTS ON CMU Blood factor products simplified FOR SPECIALISED NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES √ WILLEBRAND FACTOR COMPLEX GUIDELINES FRAMEWORK to blood factor product VIII etc INDICATIONS PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR APREMILAST NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products ARAGAM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR AVORALSTAT HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed APPROVAL APPROVAL PAEDIATRIC INDICATIONS AS PER IFR AS PER IFR BARICITINIB (WHERE ADULT TA NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL AVAILABLE) Now covered by comment 8 RESPIRATORY DISTRESS TRUST BERACTANT NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES √ Moving into tariff SYNDROME GUIDELINES

PAEDIATRIC INDICATIONS AS PER IFR AS PER IFR BRODALIMUMAB (WHERE ADULT TA NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 APPROVAL APPROVAL AVAILABLE)

CONGENITAL FACTOR XIII A- AS PER IFR AS PER IFR Blood factor products simplified CATRIDECACOG NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ SUBUNIT DEFICIENCY APPROVAL APPROVAL to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR CERTOLIZUMAB PEGOL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY)

PAEDIATRIC INDICATIONS DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR COBITOLIMOD (WHERE ADULT TA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 RESPONSE APPROVAL APPROVAL AVAILABLE) AS PER IFR AS PER IFR Changed to NRC following loss of DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL licence VIRAL HEPATITIS (B&C) & AS PER RUN RATE AS PER RUN DASABUVIR HEPATITIS C NHS ENGLAND TA 365 HEPATITIS C MDS √ √ Corrected to reflect TA status RESPIRATORY SYNCYTIAL VIRUS CARD RATE CARD PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER TA455 OR ADULT TA'S (TA103, ETANERCEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ Now covered by comment 8 MEDICINES FOR CHILDREN TA130, TA143, TA199) POLICY) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR ETROLIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN RESPONSE APPROVAL APPROVAL POLICY) HIGHLY HIGHLY FILGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY SPECIALISED SPECIALISED √ Moving into tariff CRITERIA ONLY CRITERIA ONLY NUMBER OF PATIENTS TREATED PROPORTION GIVEN TRUST FOR SPC INDICATIONS Moving into tariff but added to FILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES √ GUIDELINES WITHIN POLICY supportive drug list PRODUCT WITH LOWEST ACQUISITION COST TO BE USED PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR FILGOTINIB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN RESPONSE APPROVAL APPROVAL POLICY) VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR FILIBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products FLEBOGAMMA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products FLEBOGAMMADIF AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMAGARD AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMANORM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMAPLEX AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMUNEX AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR Blood factor products simplified GLYCOPEGYLATED FACTOR IX HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL to blood factor product VIII etc GOLIMUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS AS PER ADULTS TA'S (TA220, TA233) NICE NICE NICE AUDIT √ Now covered by comment 8 INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products HIZENTRA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS AS PER IFR AS PER IFR Immunoglobulin products HYQVIA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL simplified to IV or sc IMMUNOGLOBULINS PAEDIATRIC INDICATIONS (IN AS PER ADULT TA'S (TA130 (replaced LINE WITH NHS ENGLAND by TA375), TA134, TA140, TA143 INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ Now covered by comment 8 MEDICINES FOR CHILDREN (repalced by TA383), TA163, TA187, POLICY) TA199, TA329) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products INTRATECT AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products KIOVIG AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) NUMBER OF PATIENTS TREATED PROPORTION GIVEN TRUST FOR SPC INDICATIONS LENOGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES √ Moving into tariff GUIDELINES WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED HIGHLY HIGHLY Moving into tariff but added to LENOGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY SPECIALISED SPECIALISED √ supportive drug list CRITERIA ONLY CRITERIA ONLY AS PER IFR AS PER IFR LIPEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff APPROVAL APPROVAL PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR MAVRILIMUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN RESPONSE APPROVAL APPROVAL POLICY) VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR MOTAVIZUMAB RSV PROPHYLAXIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL BCSH Blood factor products simplified NONACOG ALPHA (BeneFIX) HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES √ GUIDELINES to blood factor product VIII etc AS PER IFR AS PER IFR Blood factor products simplified NONACOG BETA PEGOL HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL to blood factor product VIII etc INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products NORMAL IMMUNOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products OCTAGAM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR PEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff APPROVAL APPROVAL AS PER IFR AS PER IFR PEGINTERFERON LAMBDA-1A HEPATITIS C NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff APPROVAL APPROVAL PRODUCT WITH RESPIRATORY DISTRESS TRUST LOWEST PORACTANT ALFA NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES √ Moving into tariff SYNDROME GUIDELINES PROCUREMENT COST TO BE USED INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products PRIVIGEN AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) NICE AUDIT NHS ENGLAND CLINICAL PRODUCT WITH VIRAL HEPATITIS (B&C) & RIBAVIRIN HEPATITIS C NHS ENGLAND COMMISSIONING POLICY: B07/P/a; NICE NICE LOWEST √ Moving into tariff RESPIRATORY SYNCYTIAL VIRUS TA75, TA106, TA200 PROCUREMENT COST TO BE USED CRYOPYRIN-ASSOCIATED AS PER IFR AS PER IFR RILONACEPT NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff PERIODIC SYNDROMES APPROVAL APPROVAL INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products SANDOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR SARILUMAB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR SECUKINUMAB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR SETROBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL DRUGS USED IN METABOLIC AS PER IFR AS PER IFR SIALIC ACID MYOPATHY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed DISORDERS APPROVAL APPROVAL AS PER POLICY VASODILATOR ANTIHYPERTENSIVE PRODUCT WITH PULMONARY ARTERIAL NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND SILDENAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL LOWEST √ Moving into tariff HYPERTENSION COMMISSIONING POLICY: A11/P/c POLICY POLICY HYPERTENSION PROCUREMENT COST TO BE USED

PAEDIATRIC INDICATIONS DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR SIRUKUMAB (WHERE ADULT TA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 RESPONSE APPROVAL APPROVAL AVAILABLE)

INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products SUBCUVIA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products SUBGAM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR Blood factor products simplified SUSOCTOCOG ALFA (OBIZUR) HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL to blood factor product VIII etc VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND TADALAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER POLICY √ Moving into tariff HYPERTENSION COMMISSIONING POLICY: A11/P/c POLICY POLICY HYPERTENSION PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER ADULT TA'S (TA247 and TOCILIZUMAB IV NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ Now covered by comment 8 MEDICINES FOR CHILDREN TA375) POLICY) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR TOFACITINIB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL AS PER IFR AS PER IFR TREPROSTINIL DIETHANOLAMINE NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff HYPERTENSION APPROVAL APPROVAL HYPERTENSION NOT ROUTINELY COMMISSIONED VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL FOR NEW PATIENTS - NHS ENGLAND AS PER IFR AS PER IFR TREPROSTINIL SODIUM NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL √ Moving into tariff HYPERTENSION CLINICAL COMMISSIONING POLICY: APPROVAL APPROVAL HYPERTENSION A11/P/c AS PER BCSH GUIDELINES BCSH Blood factor products simplified TUROCTOCOG ALFA (NovoEight) FOR SPECIALISED NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 BCSH GUIDELINES √ GUIDELINES to blood factor product VIII etc INDICATIONS PAEDIATRIC INDICATIONS (OR DRUGS AFFECTING IMMUNE AS PER TA455 AND ADULT TA's USTEKINUMAB WHERE ADULT TA NHS ENGLAND NICE NICE NICE √ √ Now covered by comment 8 RESPONSE (TA180, TA340, TA456) AVAILABLE) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND VEDOLIZUMAB NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA's (TA 342, TA 352) NICE NICE NICE AUDIT √ √ Now covered by comment 8 MEDICINES FOR CHILDREN POLICY) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products VIGAM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products VIVAGLOBIN AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011)

9. CINACALCET FOR COMPLEX PRIMARY PARATHYROIDISM IS IN TARIFF Now excluded for all indications 10. PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS UNDER ADULT NICE OR NHS ENGLAND POLICY - THE POLICY CAN BE FOUND AT Statement added to comment 8 https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/

Lines added

DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR ANABASUM SCLERODERMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ New exclusion RESPONSE APPROVAL APPROVAL ADULT ONSET STILLS NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY √ √ DISEASE COMMISSIONING POLICY: 170056P POLICY POLICY New NHS England Policy AS PER IFR AS PER IFR ANIFROLUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR ARIMOCLOMOL NIEMANN-PICK DISEASE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AUTOLOGOUS SERUM EYE AS PER IFR AS PER IFR DRY EYE NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DROPS APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR AVACOPAN ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL AS PER IFR AS PER IFR BARDOXOLONE METHYL NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ HYPERTENSION APPROVAL APPROVAL HYPERTENSION New exclusion PERIPHERAL VASCULAR AS PER IFR AS PER IFR BEPERMINOGENE PERPLASMID NHS ENGLAND GENE THERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DISEASE APPROVAL APPROVAL New exclusion HIV IN COMBINATION WITH AS PER IFR AS PER IFR BICTECRAVIR OTHER ANTI-RETROVIRAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL DRUGS New exclusion ACUTE SENSORINEURAL AS PER IFR AS PER IFR BRIMAPITIDE NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ HEARING LOSS APPROVAL APPROVAL New exclusion X LINKED DRUGS AFFECTING THE IMMUNE BUROSUMAB NHS ENGLAND HST 8 NICE NICE NICE AUDIT √ √ HYPOPHOSPHATAEMIA RESPONSE New exclusion HIV IN COMBINATION WITH AS PER IFR AS PER IFR CABOTEGRAVIR OTHER ANTI-RETROVIRAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL DRUGS New exclusion INBORN ERRORS IN PRIMARY AS PER IFR AS PER IFR CALCIFIDIOL NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ BILE ACID SYNTHESIS APPROVAL APPROVAL New exclusion DRAVET/LENNOX GESTAUT AS PER IFR AS PER IFR CANNABIDIOL (AS EPIDIOLEX) NHS ENGLAND CANNABINOIDS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ SYNDROME APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR CENEGERMIN NEUROTROPHIC KERATITIS NHS ENGLAND ATMP NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

ANTIBODY MEDICATED AS PER IFR AS PER IFR CLAZAKIZUMAB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ REJECTION APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR CRIZANLIZUMAB SICKLE CELL DISEASE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion CYCLIC PYRANOPTERIN MOLYBDENUM COFACTOR DRUGS USED IN METABOLIC AS PER IFR AS PER IFR NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MONOPHOSPHATE DEFICIENCY DISORDERS APPROVAL APPROVAL New exclusion PRODUCT WITH DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING TRUST LOWEST DARBOPOETIN ALPHA DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS VIA OUTPATIENTS, AND ONLY AS PER TRUST GUIDELINES √ GUIDELINES PROCUREMENT COST Moved from service exclusion to - IRON OVERLOAD NICE CG114 TO BE USED full exclusion PRIMARY HYPO AND AS PER IFR AS PER IFR DICHLORPHENAMIDE HYPERKALAEMIC PERIODIC NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL PARALYSIS New exclusion AS PER IFR AS PER IFR DIROXIMEL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion DUCHENNE MUSCULAR AS PER IFR AS PER IFR DOMAGROZUMAB NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DYSTROPHY APPROVAL APPROVAL New exclusion DUCHENNE MUSCULAR AS PER IFR AS PER IFR EDASALONEXENT NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DYSTROPHY APPROVAL APPROVAL New exclusion HAEMOPHAGOCYTIC AS PER IFR AS PER IFR EMAPALUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ LYMPHOHISTIOCYTOSIS APPROVAL APPROVAL New exclusion AS PER BCSH GUIDELINES NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND PRODUCTS ON CMU EMICIZUMAB FOR SPECIALISED NHS ENGLAND BLOOD-RELATED PRODUCTS √ COMMISSIONING POLICY: 170067/P POLICY POLICY FRAMEWORK INDICATIONS New exclusion HIV IN COMBINATION WITH EMTRICITABINE +TENOFOVIR + NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND OTHER ANTI-RETROVIRAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √ DARUNAVIR + COBICISTAT COMMISSIONING POLICY: F03/P/a POLICY POLICY DRUGS New NHS England Policy HIV IN COMBINATION WITH EMTRICITABINE +TENOFOVIR + NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND OTHER ANTI-RETROVIRAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √ ELVITEGRAVIR + COBICISTAT COMMISSIONING POLICY: F03/P/a POLICY POLICY DRUGS New NHS England Policy PRODUCT WITH DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING EPOETIN ALPHA, BETA, THETA TRUST LOWEST DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS VIA OUTPATIENTS, AND ONLY AS PER TRUST GUIDELINES √ AND ZETA GUIDELINES PROCUREMENT COST Moved from service exclusion to - IRON OVERLOAD NICE CG114 TO BE USED full exclusion HYPERPARATHYROIDISM - DRUGS FOR MINERAL BONE Moved from service exclusion to ETELCALCETIDE NHS ENGLAND TA448 NICE NICE √ √ DIALYSIS PATIENTS ONLY DISORDERS full exclusion SEIZURES ASSOCIATED WITH SUBEPENDYMAL GIANT CELL NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND EVEROLIMUS (VOTUBIA®) ASTROCYTOMA (SEGA) NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: 170093P POLICY POLICY ASSOCIATED WITH TUBULAR SCLEROSIS New NHS England Policy AS PER IFR AS PER IFR GALUNISERTIB CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion GEMCITABINE (WITH NHS ENGLAND NHS ENGLAND CANCER NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY 170101P SACT √ √ CAPECITABINE) POLICY POLICY New NHS England Policy DRUGS USED IN METABOLIC AS PER IFR AS PER IFR GIVOSIRAN HEPATIC PORPHYRIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DISORDERS APPROVAL APPROVAL New exclusion HUMAN ALPHA-1 PROTEINASE AS PER IFR AS PER IFR EMPHYSEMA NHS ENGLAND DRUGS USED FOR EMPHYSEMA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ INHIBITOR APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR IMETELSTAT CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR INEBILIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR INOTERSEN AMYLOIDOSIS NHS ENGLAND UNCLASSIFIED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion MIDDLE EAST RESPIRATORY AS PER IFR AS PER IFR INTERFERON ALFA N3 IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ SYNDROME APPROVAL APPROVAL New exclusion QUALITY DASHBOARD CLINICAL GUIDELINES FOR INTRAVENOUS NORMAL HUMAN INTRAVENOUS NORMAL HUMAN NATIONAL NATIONAL NATIONAL MULTIPLE INDICATIONS NHS ENGLAND IMMUNOGLOBULIN USE, SECOND √ IMMUNOGLOBULINS IMMUNOGLOBULINS GUIDELINES GUIDELINES IMMUNOGLOBULIN EDITION UPDATE (JULY 2011) DATA BASE Replaces all IV branded names AS PER IFR AS PER IFR LANADELUMAB HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

TRUST Moved from service exclusion to LANTHANUM CARBONATE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS TRUST GUIDELINES √ GUIDELINES full exclusion HIV IN COMBINATION WITH AS PER IFR AS PER IFR LERONLIMAB OTHER ANTI-RETROVIRAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL DRUGS New exclusion AS PER IFR AS PER IFR LEVOKETOCONAZOLE CUSHING'S DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR LUSPATERCEPT CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR MARALIXIBAT ALAGILLE SYNDROME NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR MARIBAVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR MARAVIROC NATALIZUMAB INDUCED PML NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY STATEMENT AS PER IFR APPROVAL √ APPROVAL APPROVAL 170040P New NHS England Policy AS PER NHS ENGLAND CIRCULAR AS PER BLUETEQ AS PER MEXILETINE NON DYSTROPHIC MYOTONIA NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER BLUETEQ FORM √ √ New exclusion and SSC 2001 AND LETTER FORM BLUETEQ FORM commissioning position NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR NUSINERSEN SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS NHS ENGLAND POLICY STATEMENT AS PER IFR APPROVAL √ New exclusion and NHS England APPROVAL APPROVAL 170038P Policy AS PER Moved from service exclusion to PARICALCITOL HYPERPARATHYROIDISM NHS ENGLAND OTHER ENDOCRINE DRUGS AS PER CINACALCIT AS PER CINACALCIT AS PER CINACALCIT √ CINACALCIT full exclusion AS PER IFR AS PER IFR PATISIRAN AMYLOIDOSIS NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion LYSOSOMAL STORAGE DISORDER AS PER IFR AS PER IFR PEGUNIGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DRUGS APPROVAL APPROVAL New exclusion DRUGS USED IN METABOLIC AS PER IFR AS PER IFR PEGVALIASE PHENYLKETONURIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DISORDERS APPROVAL APPROVAL New exclusion DRUG RESISTANT NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND PEMBROLIZUMAB GESTATIONAL NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY NHS ENGLAND POLICY √ POLICY POLICY TROPHOBLASTIC NEOPLASIA STATEMENT: 170027P New NHS England Policy VIRAL HEPATITIS (B&C) & AS PER RUN RATE AS PER RUN PIBRENTASVIR HEPATITIS C NHS ENGLAND TA499 HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS CARD RATE CARD New exclusion PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL AS PER IFR AS PER IFR RAVULIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ HAEMOGLOBINURIA HAEMOGLOBINURIA APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR RAXIBACUMAB INHALED ANTHRAX NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion PREVENTION OF DELAYED AS PER IFR AS PER IFR REFANALIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ GRAFT FUNCTION APPROVAL APPROVAL New exclusion PREVENTION OF DELAYED AS PER IFR AS PER IFR REPARIXIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ GRAFT FUNCTION APPROVAL APPROVAL New exclusion DUCHENNE MUSCULAR AS PER IFR AS PER IFR RIMEPORIDE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DYSTROPHY APPROVAL APPROVAL New exclusion ANTI-NMDAR AUTOIMMUNE NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY √ √ ENCEPHALITIS COMMISSIONING POLICY:16036/P POLICY POLICY New NHS England Policy DERMATOMYOSITIS AND NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY √ POLYMYOSITIS (ADULTS) COMMISSIONING POLICY:16036/P POLICY POLICY New NHS England Policy NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND RITUXIMAB MYASTHENIA GRAVIS NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY √ √ POLICY POLICY 170084P New NHS England Policy HEPATIC VENO-OCCLUSIVE AS PER IFR AS PER IFR RIVIPANSEL SODIUM NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DISEASE APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR RIVIPANSEL SODIUM SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR RURIOCTOCOG ALFA PEGOL HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR RUZASVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL New exclusion CONGENITAL SUCRASE DRUGS USED IN METABOLIC AS PER IFR AS PER IFR SACROSIDASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ ISOMALTASE DEFICIENCY DISORDERS APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR SATRALIZUMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

TRUST Moved from service exclusion to SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES √ GUIDELINES full exclusion AS PER IFR AS PER IFR SIPONIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion PRODUCT WITH TA481, TA482 TRANSPLANT LOWEST SIROLIMUS (RAPAMUNE) NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √* IMMUNOSUPPRESSION ONLY PROCUREMENT COST Moved from service exclusion to REPATRIATION AGREED TO BE USED full exclusion QUALITY DASHBOARD INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR SUBCUTANEOUS HUMAN NORMAL NATIONAL NATIONAL NATIONAL Immunoglobulin products MULTIPLE INDICATIONS NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND √ IMMUNOGLOBULINS GUIDELINES GUIDELINES IMMUNOGLOBULIN simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) DATA BASE TRUST Moved from service exclusion to SUCROFERRIC OXYHDROXIDE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES √ GUIDELINES full exclusion NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND TOCILIZUMAB ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY √ √ New NHS England Policy COMMISSIONING POLICY 170056P POLICY POLICY PYRUVATE CARBOXYLASE DRUGS USED IN METABOLIC AS PER IFR AS PER IFR TRIHEPTANOIN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DEFICIENCY DISORDERS APPROVAL APPROVAL New exclusion VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR UPRIFOSBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR VATIQUINONE FRIEDREICHS ATAXIA NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion DRUGS USED TO TREAT ALPHA AS PER IFR AS PER IFR VELMANASE ALFA ALPHA MANNOSIDASE DEFICIENCYNHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MANNOSIDOSIS APPROVAL APPROVAL New exclusion MUCOPOLYSACCHARIDOSIS LYSOSOMAL STORAGE DISORDER AS PER IFR AS PER IFR VESTRONIDASE ALFA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ VII DRUGS APPROVAL APPROVAL New exclusion FAMILIAL CHYLOMICRONEMIA AS PER IFR AS PER IFR VOLANESORSEN NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ SYNDROME APPROVAL APPROVAL New exclusion VON WILLEBRAND AS PER IFR AS PER IFR VONICOG ALFA NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DEFICIENCY APPROVAL APPROVAL New exclusion RETINAL DISORDERS/INTRAOCULAR AS PER IFR AS PER IFR VORETIGENE NEPARVOVEC LEBERS DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ LENS REPLACEMENT SURGERY APPROVAL APPROVAL New exclusion

INHERITED RETINAL RETINAL DISORDERS/INTRAOCULAR AS PER IFR AS PER IFR VORETIGENE NEPARVOVEC NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ DISORDERS LENS REPLACEMENT SURGERY APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR VOXELOTOR SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion AS PER IFR AS PER IFR VX-210 SPINAL CORD INJURY NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL New exclusion

ALECTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 536 NICE NICE SACT √ √ Added for NICE TA and not listed TA 526 NOT ROUTINELY COMMISSIONED ARSENIC TRIOXIDE CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √ √ NHS ENGLAND POLICY STATEMENT Added for NICE TA and NHS 170072P England policy and not listed TA 517 NICE NICE AVELUMAB CANCER NHS ENGLAND CANCER EXCLUSION SACT √ √ CDF CDF CDF Added for NICE TA and not listed

AXICABTAGENE CILOLEUCEL CANCER CDF ATMP TA 559 CDF CDF SACT √ √ Added for NICE TA and not listed

BRIGATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA571 NICE NICE SACT √ √ Added for NICE TA and not listed

DINUTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION TA 538 NICE NICE SACT √ √ Added for NICE TA and not listed NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND DOCETAXEL CANCER NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY STATEMENT SACT √ √ Added for NHS England policy POLICY POLICY B15/PS/a and not listed

GEMTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 545 NICE NICE SACT √ √ Added for NICE TA and not listed

INOTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 541 NICE NICE SACT √ √ Added for NICE TA and not listed LIPOSOMAL CYTARABINE- CANCER NHS ENGLAND CANCER EXCLUSION TA 522 NICE NICE SACT √ √ DAUNORUBICIN Added for NICE TA and not listed SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

LUTETIUM (177Lu) CANCER NHS ENGLAND CANCER EXCLUSION TA 539 NICE NICE SACT √ √ OXODOTREOTIDE Added for NICE TA and not listed

MIDOSTAURIN CANCER NHS ENGLAND CANCER EXCLUSION TA 523 NICE NICE SACT √ √ Added for NICE TA and not listed

NIRAPARIB CANCER CDF CANCER EXCLUSION CDF (TA 528) CDF CDF SACT √ √ Added for NICE TA and not listed NICE NICE TISAGENLECLEUCEL CANCER CDF ATMP CDF (TA 554, TA567) SACT √ √ CDF CDF Added for NICE TA and not listed Lines Changed

SPECIALI SUITABLE ST FOR SUITABLE FOR CENTRE SHARED SHARED CARE ONLY CARE PRIOR WITH PRIMARY (includng BETWEEN STOPPING MONITORING/ AUDIT APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA outreach SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA SUPPORTED when AND REQUIRED BY LOCAL delivered SECONDARY PRESCRIBING as part of a CARE VIA COMMITTEE) provider NETWORK network) MODEL DRUGS AFFECTING THE IMMUNE TA312 AND NHS ENGLAND POLICY ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND NICE NICE NICE AUDIT √ √**** RESPONSE STATEMENT 170075P Updated for NHS England Policy PERIODIC FEVERS AND NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND ANAKINRA AUTOINFLAMMATORY NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: 170062P POLICY POLICY CONDITIONS Updated for NHS England Policy BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE TA 565 NICE NICE NICE AUDIT √ √ Updated for NICE TA TA129, TA228, TA311, TA 378 CDF POLICY NHS ENGLAND/ NOT ROUTINELY COMMISSIONED NICE NICE BORTEZOMIB CANCER ANTINEOPLASTIC DRUGS SACT √ CDF (NHS ENGLAND CLINICAL CDF CDF COMMISSIONING POLICY: 170035P, 170074P) Updated for NHS England Policy NOT ROUTINELY COMMISSIONED NEURONAL CEROID LYSOSOMAL STORAGE DISORDER NHS ENGLAND POLCIY STATEMENT AS PER IFR AS PER IFR CERLIPONASE ALFA NHS ENGLAND AS PER IFR APPROVAL √ LIPOFUSCINOSIS DRUGS 170017/P APPROVAL APPROVAL Updated for NHS England Policy NICE NICE DRUGS FOR MINERAL BONE TA117 CINACALCET HYPERPARATHYROIDISM NHS ENGLAND NHS ENGLAND NHS ENGLAND √ DISORDERS NHS ENGLAND POLICY 16034/P POLICY POLICY Updated for NHS England Policy NHS ENGLAND/ NICE TA 406, 422 NICE NICE CRIZOTINIB CANCER PROTEIN KINASE INHIBITORS SACT √ √ CDF CDF (TA 529) CDF CDF Updated for NICE TA DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, TA396 & TA 544 NICE NICE SACT √ (not TA321) √ Updated for NICE TA NHS ENGLAND/ NICE NICE DASATINIB CANCER PROTEIN KINASE INHIBITORS NICE TA 425, 426 SACT √ CDF CDF CDF Reference to CDF removed TA527 & NHS ENGLAND POLICY: NHS ENGLAND NHS ENGLAND GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS AS PER NHSE POLICY √ √**** D04/P/b POLICY POLICY Updated for NICE MTA NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR INFLIXIMAB PULMONARY SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL √ NHS ENGAND POLICY 170088P APPROVAL APPROVAL Updated for NHS England Policy TA 527 NHS ENGLAND NHS ENGLAND INTERFERON BETA MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS AS PER NHSE POLICY √ √**** NHS ENGLAND POLICY: D04/P/b POLICY POLICY Updated for NICE MTA NHS ENGLAND/ TA171, TA322 NICE NICE LENALIDOMIDE CANCER IMMUNOMODULATING DRUGS SACT √ CDF CDF POLICY CDF CDF Reference to CDF removed NHS ENGLAND NHS ENGLAND LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY 170078P NHS ENGLAND POLICY √ POLICY POLICY Updated for NHS England Policy HOMOZYGOUS FAMILIAL NHS ENGLAND NHS ENGLAND LOMITAPIDE NHS ENGLAND LIPID-REGULATING DRUGS NHS ENGLAND POLICY 170059P NHS ENGLAND POLICY √ HYPERCHOLESTEROLEMIA POLICY POLICY Updated for NHS England Policy NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND METRELEPTIN DYSLIPIDAEMIA NHS ENGLAND OTHER ENDOCRINE DRUGS AS PER POLICY √ COMMISSIONING POLICY: 170095P POLICY POLICY Updated for NHS England Policy DRUGS AFFECTING THE IMMUNE OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND TA 533 NICE NICE NICE AUDIT √ √**** RESPONSE Updated for NICE TA SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

TA 357, TA366, TA428, TA531 NHS CDF POLICY (TA 447 (replaced by NICE NICE PEMBROLIZUMAB CANCER INDICATIONS CANCER EXCLUSION SACT √ √ ENGLAND/CDF TA531), TA 519, TA522 TA540, TA553 & CDF CDF TA557) Updated for NICE TA REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 & TA555 NICE NICE SACT √ √ Updated for NICE TA CONNECTIVE TISSUE NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR RITUXIMAB DISEASE - INTERSTITIAL NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL √ NHS ENGLAND POLICY 170015/P APPROVAL APPROVAL LUNG DISEASE Updated for NHS England Policy CHRONIC INFLAMMATORY NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR RITUXIMAB DEMYELINATING NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL √ NHS ENGLAND POLICY 170026/P APPROVAL APPROVAL POLYNEUROPATHY Updated for NHS England Policy MEMBRANOUS NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL √ NEPHROPATHY NHS ENGLAND POLICY 16047/P APPROVAL APPROVAL Updated for NHS England Policy PRIMARY SJOGREN'S NOT ROUTINELY COMMISSIONED AS PER IFR AS PER IFR RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL √ SYNDROME (PSS) NHS ENGLAND POLICY 16048/P APPROVAL APPROVAL Updated for NHS England Policy NOT ROUTINELY COMMISSIONED ADULTS AND CHILDREN WITH DRUGS USED IN METABOLIC AS PER IFR AS PER IFR SAPROPTERIN NHS ENGLAND (NHS ENGLAND CLINICAL AS PER IFR APPROVAL √ PHENYLKETONURIA DISORDERS APPROVAL APPROVAL COMMISSIONING POLICY: 170103P) Updated for NHS England Policy VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND SELEXIPAG NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY √ HYPERTENSION COMMISSIONING POLICY: 170104P POLICY POLICY HYPERTENSION Updated for NHS England Policy SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 & TA 535 NICE NICE SACT √ √ Updated for NICE TA NOT ROUTINELY COMMISSIONED Reference to CDF removed and TEMSIROLIMUS CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √ (TA178) NRC added NHS ENGLAND CLINICAL MALE AND JUVENILE DRUGS AFFECTING BONE NHS ENGLAND NHS ENGLAND TERIPARATIDE NHS ENGLAND COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY √ OSTEOPOROSIS METABOLISM POLICY POLICY 170064P Updated for NHS England Policy TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS TA 518 NICE NICE NICE AUDIT √ √ Updated for NICE TA NHS ENGLAND CLINICAL JUVENILE ARTHRITIS- NHS ENGLAND NHS ENGLAND TOCILIZUMAB IV NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY √ √ Removed reference to IV as SC PAEDIATRIC POLICY POLICY 373 now licensed for JIA DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL NHS ENGLAND NHS ENGLAND TRIENTENE WILSONS DISEASE NHS ENGLAND NHS ENGLAND POLICY √ √ DISORDERS COMMISSIONING POLICY 170094P POLICY POLICY Updated for NHS England Policy NOT ROUTINELY COMMISSIONED VANDETANIB THYROID CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √ (TA550) Updated for NICE TA NHS ENGLAND/ TA 520 & TA 525 NICE NICE ATEZOLIZUMAB CANCER CANCER EXCLUSION SACT √ √ CDF CDF (TA 492) CDF CDF Updated for NICE TA AUTOLOGOUS CHONDROCYTE ARTICULAR CARTILAGE NHS ENGLAND TA 477 & TA 508 NICE NICE NICE AUDIT √ √ IMPLANTATION DEFECT Updated for NICE TA TA216 NICE NICE CDF POLICY NHS ENGLAND/ CDF CDF √ (Not for all BENDAMUSTINE CANCER CANCER EXCLUSION NHS ENGLAND POLICY (WITH SACT √ CDF NHS ENGLAND NHS ENGLAND policies) RITUXIMAB) 170055P, 17088P & POLICY POLICY 170054P Updated for NHS England Policy TA446 (replaced by TA524), TA478, NHS ENGLAND/ NICE NICE BRENTUXIMAB CANCER CANCER EXCLUSION TA524 SACT √ √ Updated for NICE TA CDF CDF CDF CDF POLICY Reference to CDF removed NHS Updated for NICE TA CABOZANTINIB CANCER CANCER EXCLUSION TA 463, TA516 & TA 542 NICE NICE SACT √ √ ENGLAND/CDF Reference to CDF removed NHS ENGLAND/ NICE TA 423 NICE NICE ERIBULIN CANCER CANCER EXCLUSION SACT √ √ CDF CDF POLICY CDF CDF Blueteq requirement added NHS TA429, TA502 NICE NICE IBRUTINIB CANCER PROTEIN KINASE INHIBITORS SACT √ √ ENGLAND/CDF CDF (TA491) CDF CDF Updated for NICE TA LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498, TA 535 & TA 551 NICE NICE SACT √ √ Updated for NICE TA NHS TA 384, 400, 417, 462, 530 NICE NICE NIVOLUMAB CANCER CANCER EXCLUSION SACT √ √ ENGLAND/CDF CDF (TA 483, TA 484, TA 490, TA 558,) CDF CDF Updated for NICE TA OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √ √ Blueteq requirement added PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424, TA 509 and TA 569 NICE NICE SACT √ √ Updated for NICE TA NHS ENGLAND/ NICE NICE RADIUM-223 DICHLORIDE CANCER CANCER EXCLUSION NICE TA 376, TA 412 SACT √ CDF CDF CDF Reference to CDF removed TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √ √ Blueteq requirement added TIVOZANIB CANCER CDF CANCER EXCLUSION TA 512 CDF CDF SACT √ √ Reference to CDF removed SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL

TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 & TA 544 NICE NICE SACT √ √ Updated for NICE TA TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √ √ Blueteq requirement added

8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY FOUND AT https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/ AND A BLUETEQ FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISISONED BY Updated to include link to the M4C policy CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFLIXIMAB ETC PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS